Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
Ilie SM, Briot N, Constantin G, Roussot N, Ilie A, Bergeron A, Arnould L, Beltjens F, Desmoulin I, Mayeur D, Kaderbhai C, Hennequin A, Jankowski C, Padeano MM, Costaz H, Amet A, Coutant C, Coudert B, Bertaut A, Ladoire S. Ilie SM, et al. Among authors: ilie a. Breast Cancer. 2023 Nov;30(6):997-1007. doi: 10.1007/s12282-023-01490-1. Epub 2023 Aug 10. Breast Cancer. 2023. PMID: 37561255 Free PMC article.
CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapy.
Schoumacher C, Derangère V, Gaudillière-Le Dain G, Huppe T, Rageot D, Ilie A, Vienot A, Borg C, Monnien F, Bibeau F, Truntzer C, Ghiringhelli F; CGE-Pancreas investigators. Schoumacher C, et al. Among authors: ilie a. Oncoimmunology. 2023 Dec 21;13(1):2294563. doi: 10.1080/2162402X.2023.2294563. eCollection 2024. Oncoimmunology. 2023. PMID: 38169969 Free PMC article.
Pathologic and immunohistochemical prognostic markers in residual triple-negative breast cancer after neoadjuvant chemotherapy.
Ilie SM, Briot N, Constatin G, Ilie A, Beltjens F, Ladoire S, Desmoulins I, Hennequin A, Bertaut A, Coutant C, Causeret S, Ghozali N, Coudert B, Arnould L. Ilie SM, et al. Among authors: ilie a. Front Oncol. 2024 Jan 10;13:1309890. doi: 10.3389/fonc.2023.1309890. eCollection 2023. Front Oncol. 2024. PMID: 38273853 Free PMC article.
Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer.
Derangère V, Lecuelle J, Lepage C, Aoulad-Ben Salem O, Allatessem BM, Ilie A, Bouché O, Phelip JM, Baconnier M, Pezet D, Sebbagh V, Terrebonne E, Bouard G, Jooste V, Bouvier AM, Molimard C, Monnien F, Gonzalez D, Le Malicot K, Rageot D, Truntzer C, Bibeau F, Ghiringhelli F; PRODIGE 13 investigators and collaborators. Derangère V, et al. Among authors: ilie a. Eur J Cancer. 2022 Sep;172:221-230. doi: 10.1016/j.ejca.2022.05.040. Epub 2022 Jul 1. Eur J Cancer. 2022. PMID: 35785606 Free article.
Heat shock and HSP70 regulate 5-FU-mediated caspase-1 activation in myeloid-derived suppressor cells and tumor growth in mice.
Pilot T, Fratti A, Thinselin C, Perrichet A, Demontoux L, Limagne E, Derangère V, Ilie A, Ndiaye M, Jacquin E, Garrido C, Ghiringhelli F, Chalmin F, Rébé C. Pilot T, et al. Among authors: ilie a. J Immunother Cancer. 2020 May;8(1):e000478. doi: 10.1136/jitc-2019-000478. J Immunother Cancer. 2020. PMID: 32385145 Free PMC article.
Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer.
Ghiringhelli F, Bibeau F, Greillier L, Fumet JD, Ilie A, Monville F, Laugé C, Catteau A, Boquet I, Majdi A, Morgand E, Oulkhouir Y, Brandone N, Adam J, Sbarrato T, Kassambara A, Fieschi J, Garcia S, Lepage AL, Tomasini P, Galon J. Ghiringhelli F, et al. Among authors: ilie a. EBioMedicine. 2023 Jun;92:104633. doi: 10.1016/j.ebiom.2023.104633. Epub 2023 May 25. EBioMedicine. 2023. PMID: 37244159 Free PMC article.
141 results